Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The study showed a significant association of genetic polymorphisms (CYP2C19*2 G>A and GPVI T>C) with DAPT non-responsiveness in MI patients.
|
31571629 |
2019 |
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariable Cox regression analysis confirmed the <i>AKR1D1*36 allele</i> as an independent risk factor (HR = 2.36; 95% CI, 1.34 to 4.18) and identified 3 other risk factors for MACCE; previous percutaneous interventions (PCI), HR = 2.78; (95% CI, 1.34 to 5.78), and a history of myocardial infarction, HR = 2.62; (95% CI, 1.48 to 4.64) at baseline and the previously reported <i>CYP2C19*2</i> polymorphism (HR = 2.33; 95% CI, 1.33 to 4.06).
|
31695473 |
2019 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among predictors associated with MACE was the carriage of one CYP2C19 loss of function allele {hazard ratio (HR) 8.6 [confidence interval (CI) 3.15-23.4]; P < 0.0005}, hypertension [HR 3.74 (CI 1.06-13.16); P = 0.04], reduced ventricular function [HR 3.88 (1.43-10.54); P = 0.008], and history of previous myocardial infarction [HR 4.9 (CI 1.48-11.33); P = 0.007] by univariate analysis, although only CYP2C19 genotype remained significant by multivariate analysis [HR 11.88 (CI 3.25-43.44); P < 0.0005].
|
29554005 |
2018 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Platelet reactivity was assessed by light transmittance aggregometry (LTA) and matched with various CYP2C19 loss-of-function genetic polymorphisms and major adverse clinical events (composite of vascular deaths, stroke/transient ischemic attack, and myocardial infarction).
|
29509167 |
2018 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The highest level of association with clopidogrel response status was found for CYP2C19 polymorphisms, concomitant aspirin treatment, leukocyte and platelet count, history of myocardial infarction, arterial hypertension, and ward where patients were admitted.
|
26873108 |
2017 |
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no association between CYP2C19 metabolizer status (EM vs. RM) and the primary composite endpoint of cardiovascular death, myocardial infarction (MI), or stroke (hazard ratio [HR]: 0.86).
|
26916483 |
2016 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of CYP2C19 have been associated with variant risk of subsequent cardiovascular events in survivors of myocardial infarction (MI) receiving clopidogrel.
|
25207801 |
2015 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with non-carriers of the CYP2C19 variant allele, the carriers were found to have an increased risk of adverse clinical events (OR 1.50, 95% CI 1.21-1.87; P=0.0003), myocardial infarction (OR 1.62, 95% CI 1.35-1.95; P<0.00001), stent thrombosis (OR 2.08, 95% CI 1.67-2.60; P<0.00001), ischaemic stroke (OR 2.14, 95% CI 1.36-3.38; P=0.001) and repeat revascularization (OR 1.35, 95% CI 1.10-1.66; P=0.004), but not of mortality (P=0.500) and bleeding events (P=0.930).
|
24080325 |
2013 |
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association of COX1 was driven by mortality related events whereas that of CYP2C19*2 was mainly attributed to myocardial infarction and stent thrombosis.
|
22940005 |
2013 |
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 2-year cumulative event rates for bleeding [*wt/*17 vs. *wt/*wt: 2 vs. 2.3%; adjusted hazard ratio (HR), 1.23; 95% confidence interval (CI), 0.16-9.45], stent thrombosis (2 vs. 1.1%; HR, 3.98; 95% CI, 0.49-31.6) or composite of any death, and myocardial infarction or stroke (5.4 vs. 7.1%; HR, 1.37; 95% CI, 0.32-5.73) did not differ on the basis of the presence of CYP2C19*17.
|
23922007 |
2013 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19*2 genetic variant may be associated with worse outcome in Korean patients treated exclusively with DES and dual-antiplatelet therapy due to a significant increase in cardiac death, myocardial infarction or stent thrombosis.
|
21700758 |
2012 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The summary OR showed a significant association between CYP2C19 LOF variants and an increased risk of cardiac death (OR 2.18, 95% CI 1.37 to 3.47), myocardial infarction (OR 1.42, 95% CI 1.12 to 1.81), and stent thrombosis (OR 2.41, 95% CI 1.76 to 3.30).
|
22591668 |
2012 |
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Variants in ABCB1 and CYP2C19 have been identified as predictors of cardiac events during clopidogrel therapy initiated after myocardial infarction (MI) or percutaneous coronary intervention (PCI).
|
22190063 |
2012 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the association of the presence of the ABCB1 (C/T) T-allele, CYP2C19*2 (G/A) A-allele, or CYP2C19*17 (C/T) T-allele with the primary end point of the need of clinically-driven target lesion revascularization (TLR) and the secondary end points of major adverse cardiovascular events (MACE; including death, myocardial infarction [MI], and TLR) at 1 year in a high-risk population of 928 patients with acute MI.
|
20826260 |
2010 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
We then assessed the relation of allelic variants of genes modulating clopidogrel absorption (ABCB1), metabolic activation (CYP3A5 and CYP2C19), and biologic activity (P2RY12 and ITGB3) to the risk of death from any cause, nonfatal stroke, or myocardial infarction during 1 year of follow-up.
|
19106083 |
2009 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We then assessed the relation of allelic variants of genes modulating clopidogrel absorption (ABCB1), metabolic activation (CYP3A5 and CYP2C19), and biologic activity (P2RY12 and ITGB3) to the risk of death from any cause, nonfatal stroke, or myocardial infarction during 1 year of follow-up.
|
19106083 |
2009 |
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19*2 genetic variant is a major determinant of prognosis in young patients who are receiving clopidogrel treatment after myocardial infarction.
|
19108880 |
2009 |